NCT04308642View on ClinicalTrials.gov

Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy

CompletedOBSERVATIONAL
Enrollment

6

Participants

Timeline

Start Date

October 22, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Kidney Impairment
Interventions
OTHER

blood test for renal biomarkers

blood test for renal biomarkers (uromodulin,Neutrophil gelatinase-associated lipocalin, beta-trace protein, creatinine, cystatin C)

OTHER

urine test for renal biomarkers

urine test for renal biomarkers (uromodulin, alpha-1 microglobulin, retinol-binding protein, Neutrophil gelatinase-associated lipocalin (NGAL), beta-trace protein, cylinder, albumin, immunoglobulin G (IgG), transferrin, creatinine)

Trial Locations (1)

4056

University Children's Hospital Basel (UKBB), University of Basel, Basel

All Listed Sponsors
collaborator

Stiftung für Krebskranke Kinder

UNKNOWN

lead

University Hospital, Basel, Switzerland

OTHER

NCT04308642 - Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy | Biotech Hunter | Biotech Hunter